Featured Research

from universities, journals, and other organizations

HIV vaccines may induce HIV antibodies in trial participants, can cause false-positive test result

Date:
July 22, 2010
Source:
JAMA and Archives Journals
Summary:
During trials of preventive HIV vaccines, trial participants may develop HIV-related antibody responses that could lead to a positive HIV test by routine antibody detection methods (called vaccine-induced seropositivity/reactivity [VISP]), and the potential for false-positive test results and an incorrect HIV diagnosis, according to a new study.

During trials of preventive HIV vaccines, trial participants may develop HIV-related antibody responses that could lead to a positive HIV test by routine antibody detection methods (called vaccine-induced seropositivity/reactivity [VISP]), and the potential for false-positive test results and an incorrect HIV diagnosis, according to a study in the July 21 issue of JAMA, a theme issue on HIV/AIDS.

Lindsey R. Baden, M.D., of Brigham and Women's Hospital and Harvard Medical School, Boston, presented the findings of the study at a JAMA media briefing at the International AIDS conference in Vienna.

"With an estimated 7,500 new human immunodeficiency virus (HIV) infections occurring each day worldwide, there is an urgent need to develop an effective prophylactic HIV vaccine. Over the last 20 years many potential vaccine candidates have been developed and assessed in human clinical trials in more than 30,000 participants," the authors write. They add that induction of protective anti-HIV immune responses is the goal of an HIV vaccine. However, this may cause a reactive result in routine HIV testing in the absence of HIV infection, and has the potential of confounding (factors that can improperly skew outcomes) interpretation of HIV tests because of the antibody induced by vaccination. "Participants in early phase clinical trials, who are typically at low risk of HIV infection, may encounter difficulties with obtaining medical or disability/life insurance, donating blood or organs, employment, and immigration owing to a false-positive HIV test result."

Dr. Baden and colleagues assessed the occurrence of VISP associated with different vaccine delivery systems and HIV inserts (targets) studied by the HIV Vaccine Trials Network (HVTN). Three common U.S. Food and Drug Administration-approved enzyme immunoassay (EIA) HIV antibody kits were used to determine VISP, and a routine diagnostic HIV algorithm was used to evaluate VISP frequency in healthy, HIV-seronegative adults who completed phase 1 (n = 25) and phase 2a (n = 2) vaccine trials conducted from 2000-2010 in the United States, South America, Thailand, and Africa. The majority of participants (82 percent) in the analysis were from the United States.

VISP occurred in 908 of 2,176 participants (41.7 percent). Rates of VISP varied greatly by type of HIV vaccine administered. For poxvirus products given alone or as a boost to a DNA or poxvirus prime, 53.4 percent (295 of 552) of recipients had VISP; 86.7 percent (399 of 460) of adenovirus 5 product recipients developed VISP, as did 35 of 555 (6.3 percent) of DNA-alone product recipients.

Overall, the proportion of VISP among the various HIV testing kits tested ranged from about 41 percent to 9 percent. The researchers also found that among the 901 participants with VISP and a Western blot result (a technique in molecular biology, used to separate and identify proteins), 92 (10.2 percent) had a positive result, 592 (65.7 percent) tested indeterminate, and 217 (24.1 percent) tested negative; however, the distribution of results varied by product.

"These data demonstrate that VISP is a common but highly variable outcome of trials of preventive HIV vaccines," the authors write. "Because participants with VISP may subsequently become infected with HIV, it is imperative that appropriate follow-up testing be conducted, including HIV RNA testing, to minimize potential misinterpretation of HIV test results."

"Testing for VISP at the end of the study and providing participants with their VISP status is critically important to prevent social harms, incorrect HIV diagnosis, and inaccurate reporting to health agencies. A misinterpretation of VISP can be minimized by clinicians obtaining a complete patient history (e.g., participation in an HIV vaccine trial) and interpretation of the Western blot and HIV RNA."


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. Cristine J. Cooper; Barbara Metch; Joan Dragavon; Robert W. Coombs; Lindsey R. Baden; for the NIAID HIV Vaccine Trials Network (HVTN) Vaccine-Induced Seropositivity (VISP) Task Force. Vaccine-Induced HIV Seropositivity/Reactivity in Noninfected HIV Vaccine Recipients. JAMA, 2010; 304 (3): 275-283 [link]

Cite This Page:

JAMA and Archives Journals. "HIV vaccines may induce HIV antibodies in trial participants, can cause false-positive test result." ScienceDaily. ScienceDaily, 22 July 2010. <www.sciencedaily.com/releases/2010/07/100718204741.htm>.
JAMA and Archives Journals. (2010, July 22). HIV vaccines may induce HIV antibodies in trial participants, can cause false-positive test result. ScienceDaily. Retrieved July 28, 2014 from www.sciencedaily.com/releases/2010/07/100718204741.htm
JAMA and Archives Journals. "HIV vaccines may induce HIV antibodies in trial participants, can cause false-positive test result." ScienceDaily. www.sciencedaily.com/releases/2010/07/100718204741.htm (accessed July 28, 2014).

Share This




More Health & Medicine News

Monday, July 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Trees Could Save More Than 850 Lives Each Year

Trees Could Save More Than 850 Lives Each Year

Newsy (July 27, 2014) A national study conducted by the USDA Forest Service found that trees collectively save more than 850 lives on an annual basis. Video provided by Newsy
Powered by NewsLook.com
Google's Next Frontier: The Human Body

Google's Next Frontier: The Human Body

Newsy (July 27, 2014) Google is collecting genetic and molecular information to paint a picture of the perfectly healthy human. Video provided by Newsy
Powered by NewsLook.com
What's To Blame For Worst Ebola Outbreak In History?

What's To Blame For Worst Ebola Outbreak In History?

Newsy (July 27, 2014) A U.S. doctor has tested positive for the deadly Ebola virus, as the worst-ever outbreak continues to grow. Video provided by Newsy
Powered by NewsLook.com
Losing Sleep Leaves You Vulnerable To 'False Memories'

Losing Sleep Leaves You Vulnerable To 'False Memories'

Newsy (July 27, 2014) A new study shows sleep deprivation can make it harder for people to remember specific details of an event. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins